SCHEMBL4429931

SCHEMBL4429931

O=CNc1cccc(-c2ccc(C(=O)O)cc2)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRIM24 O15164 1/20 0.59
TRIM33 Q9UPN9 1/20 0.59
RXRA P19793 4/20 0.50
RXRB P28702 4/20 0.50
MAPK8 P45983 1/20 0.50
PIK3CG P48736 1/20 0.50
GSK3B P49841 1/20 0.50
CAMKK2 Q96RR4 1/20 0.50
RXRG P48443 1/20 0.50
BCL2 P10415 1/20 0.50
KDM5A P29375 1/20 0.49
MGLL Q99685 1/20 0.49
ERN1 O75460 1/20 0.47
EGFR P00533 1/20 0.47
KMO O15229 1/20 0.47
SYK P43405 1/20 0.47
KDM4E B2RXH2 1/20 0.46
MEN1 O00255 1/20 0.46
NPC1 O15118 1/20 0.46
ALDH1A1 P00352 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3211380 0.85 TRIM24 (0.45) TRIM24TRIM33RXRARXRBKDM5A
SCHEMBL8967589 0.84 ALDH1A1 (0.64) MGLLMEN1ALDH1A1KMT2A
SCHEMBL28214132 0.84 ALDH1A1 (0.56) MGLLMEN1ALDH1A1KMT2A
SCHEMBL4428955 0.83 ALDH1A1 (0.50) TRIM24TRIM33RXRARXRBKDM5A
SCHEMBL171243 0.81 RAB9A (0.55) KDM5AMEN1NPC1ALDH1A1RAB9A
SCHEMBL30066684 0.78 KMO (0.72) TRIM24TRIM33RXRARXRBRXRG
SCHEMBL16166011 0.78 KMO (0.72) TRIM24TRIM33RXRARXRBRXRG
SCHEMBL1749196 0.77 MEN1 (0.59) RXRARXRBRXRGBCL2MGLL
SCHEMBL29906143 0.77 KMO (0.76) TRIM24TRIM33RXRARXRBRXRG
SCHEMBL2346605 0.77 KMO (0.76) TRIM24TRIM33RXRARXRBRXRG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7538121-B2 Vanilloid receptor modulators GLAXO GROUP LIMITED (GB) 2009-05-26 US disclosed
EP-2033953-A1 Vanilloid receptor modulators Glaxo Group Limited (GB) 2009-03-11 EP disclosed
US-20060142333-A1 Vanilloid receptor modulators MACDONALD GREGOR J 2006-06-29 US disclosed
EP-1480954-A1 VANILLOID RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2004-12-01 EP disclosed
WO-2003068749-A1 VANILLOID RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2003-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060142333-A1 Vanilloid receptor modulators TRPV1, NPSR1, TRPV3 TRIM24 4528/4885TRIM33 4588/4885RXRA 415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.